I
n its most recent recommendation statement on colorectal cancer (CRC) screening, the U.S. Preventive Services Task Force (USPSTF) recommends screening using fecal occult blood testing, sigmoidoscopy, or colonoscopy, starting at age 50 years and continuing up to age 75 years (1) . The USPSTF recommends against routine screening in persons older than 75 years with an adequate screening history (1) . This latter recommendation is warranted by an analysis showing that the benefits of continuing screening from age 50 to 85 years instead of 75 years do not justify the additional colonoscopies required (2) . Although the USPSTF did not address the appropriateness of screening in inadequately screened elderly persons, this recommendation has led many members of the medical community to believe that no one older than 75 years should be screened for CRC (3, 4) . However, because unscreened elderly persons are at greater risk for CRC than adequately screened elderly persons, screening them is likely to be effective and cost-effective up to a more advanced age. If so, the lack of more specific recommendations on the age to stop screening may result in an unfounded denial of access to screening in elderly persons who were never screened for CRC-a group representing 23% of all U.S. persons older than 75 years (5) .
Many other elderly persons continue to be screened up to their late 80s or early 90s (6) . However, at these ages, screening is not likely to be cost-effective, even in those without previous screening. First, the high risk for death of competing disease at advanced age tends to offset the benefits of screening (7, 8) . Second, the risks for screeninginduced harms (colonoscopy-related complications and overdiagnosis and overtreatment of CRC) increase with increasing age (9) .
The objective of this study was to determine up to what age CRC screening should be considered in elderly persons without previous screening and to determine which screening test-colonoscopy, sigmoidoscopy, or fecal immunochemical test (FIT)-is indicated at what age.
We performed separate analyses for elderly persons with no, moderate, and severe comorbid conditions because the effectiveness and cost-effectiveness of screening depend heavily on a person's life expectancy.
METHODS
We used the Microsimulation Screening AnalysisColon (MISCAN-Colon) model (Erasmus University Medical Center, Rotterdam, the Netherlands) to quantify the effectiveness and costs of screening.
MISCAN-Colon
MISCAN-Colon is a well-established microsimulation model for CRC developed at the Department of Public Health of the Erasmus University Medical Center. The model's structure, underlying assumptions, and calibration are described in the Appendix (available at www.annals .org). In brief, MISCAN-Colon simulates the life histories of a large population from birth to death. As each simulated person ages, 1 or more adenomas may develop. These adenomas can progress from small (Յ5 mm) to medium (6 to 9 mm) to large (Ն10 mm) size. Some adenomas can develop into preclinical cancer, which may progress through stages I to IV. During each stage, CRC may be diagnosed because of symptoms. Survival after clinical diagnosis is determined by the stage at diagnosis, the localization of the cancer, and the person's age (10) .
Screening will alter some of the simulated life histories: Some cancer cases will be prevented by the detection and removal of adenomas; other cancer cases will be detected in an earlier stage with a more favorable survival. However, screening can also result in serious complications and overdiagnosis and overtreatment of CRC (that is, the detection and treatment of cancer that would not have been diagnosed without screening). By comparing all life histories with screening with the corresponding life histories without screening, MISCAN-Colon quantifies the effectiveness of screening as well as the associated costs.
MISCAN-Colon was calibrated to the age-, stage-, and localization-specific incidence of CRC as seen in the SEER (Surveillance, Epidemiology, and End Results) Program before the introduction of screening (that is, between 1975 and 1979) and the age-specific prevalence and multiplicity distribution of adenomas seen in autopsy studies (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . The preclinical duration of CRC and the adenoma dwell time were calibrated to the rates of interval and surveillance-detected cancer seen in randomized, controlled trials evaluating screening using guaiac fecal occult blood tests and a 1-time sigmoidoscopy (22) (23) (24) (25) (26) .
Model Inputs Populations Simulated
For each age between 76 and 90 years, we simulated a cohort of 10 million elderly persons without previous screening with no, moderate, and severe comorbid conditions (a total of 45 cohorts). Compared with cohorts of adequately screened elderly persons, the risk for CRC in these cohorts was substantially greater: CRC and adenomas were prevalent in 0.3% and 14.1%, respectively, of simulated patients aged 80 years with negative screening colonoscopies at ages 50, 60, and 70 years and in 2.6% and 44.9%, respectively, of simulated patients aged 80 years without previous screening.
We used comorbid condition level-specific life tables to simulate elderly persons with no, moderate, and severe comorbid conditions (27) . Persons are classified as having moderate comorbid conditions if they have an ulcer, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, cerebrovascular disease, or a history of acute myocardial infarction; severe comorbid conditions if they have chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and no comorbid conditions if none of these conditions are present.
Screening Strategies
We simulated 1-time colonoscopy, 1-time sigmoidoscopy, and 1-time FIT screening within each cohort. Test characteristics and complication rates for each screening test are given in Appendix Table 1 (available at www .annals.org). Patients with an adenoma or CRC detected during sigmoidoscopy or with a positive FIT result were referred for a diagnostic colonoscopy. Persons with adenomas detected and removed during a screening or diagnostic colonoscopy were assumed to have colonoscopy surveillance according to the current guidelines (28) . We assumed that surveillance continued until the diagnosis of CRC or
Context
Some guidelines caution against routine screening for colorectal cancer in persons older than 75 years who have already been screened, but these guidelines ignore persons who have not been screened.
Contribution
This study estimates that screening persons who have not been screened has good value up to age 86 years for persons with no comorbid conditions, up to age 83 years for those with moderate comorbid conditions, and up to age 80 years for those with severe comorbid conditions.
Caution
Only persons at average risk for colorectal cancer were studied.
Implication
Screening should be considered for some persons older than 75 years who have not already been screened.
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Original Research death. Adherence to screening and diagnostic and surveillance colonoscopies was assumed to be 100%. We restricted ourselves to 1-time colonoscopy and 1-time sigmoidoscopy screening because performing more screening colonoscopies or sigmoidoscopies is unlikely to be cost-effective at older age. We explored the effect of FIT screening during 2 consecutive years in a sensitivity analysis.
Utility Losses Associated With CRC Screening
We assumed a utility loss (that is, a loss of quality of life) equal to 2 full days of life per colonoscopy (0.0055 quality-adjusted life-years [QALYs]), 1 day of life per sigmoidoscopy (0.0027 QALYs), and 2 weeks of life per complication (0.0384 QALYs) ( Table 1) . We also assigned a utility loss to each LY with CRC care (29) .
The assignment of utility losses to LYs with CRC care works 2 ways: On the one hand, screening prevents cancer by the detection and removal of adenomas, thereby reducing LYs with CRC care and hence resulting in a gain of quality of life. On the other hand, screening results in overdiagnosis and overtreatment of cancer, resulting in LYs with CRC care in persons who would never have been diagnosed with CRC without screening and hence a loss of quality of life. The net effect on quality of life depends on the balance between cancer cases prevented and cancer cases overdiagnosed and can be either positive or negative.
Costs Associated With CRC Screening
The cost-effectiveness analyses were conducted from a societal perspective. The costs of colonoscopy, sigmoidoscopy, and FIT were based on 2007 Medicare payment Stage I CRC  -36 683  3050  63 809  19 176  Stage II CRC  -49 234  2870  63 555  17 279  Stage III CRC  -59 759  4021  67 041  21 457  Stage IV CRC  -77 790  12 178  88 368  49 866 CRC ϭ colorectal cancer; FIT ϭ fecal immunochemical test; LY ϭ life-year; QALY ϭ quality-adjusted life-year. * The loss of quality of life associated with a particular event.
† Care for CRC was divided in 3 clinically relevant phases: initial, continuing, and terminal care. The initial care phase was defined as the first 12 mo after diagnosis; the terminal care phase was defined as the final 12 mo of life; the continuing care phase was defined as all months in between. In the terminal care phase, we distinguished between patients with CRC who were dying of CRC and those dying of another cause. For patients surviving less than 24 mo, the final 12 mo were allocated to the terminal care phase and the remaining months were allocated to the initial care phase. ‡ Utility losses for LYs with initial care were derived from a study by Ness et al (29 (31) . We adjusted all costs to reflect the 2013 level using the U.S. Consumer Price Index (34). The assignment of costs to LYs with CRC care also works 2 ways: On the one hand, screening prevents cancer, reducing the costs of CRC care. On the other hand, screening results in overtreatment of cancer, increasing these costs. The net effect can be either a reduction or an increase in costs.
Outcomes
For each cohort, we quantified the effectiveness (that is, the number of CRC cases prevented, CRC deaths prevented, LYs gained, and QALYs gained) and costs of 1-time colonoscopy, sigmoidoscopy, and FIT screening, applying the conventional 3% annual discount rate for both.
Analyses
We first determined the cost-effectiveness of each screening strategy compared with no screening for all cohorts. For each comorbid condition level, we determined the upper age at which each screening strategy was costeffective compared with no screening, assuming a willingness to pay per QALY gained of $100 000.
We subsequently performed an analysis to determine the optimal screening strategy for each cohort (that is, the most effective, still cost-effective screening strategy). To do so, we first excluded all dominated screening strategies (that is, those that were more costly and less effective than other strategies or combinations of other strategies). We determined the incremental cost-effectiveness ratio for all remaining strategies ("efficient strategies"): the additional costs per additional QALY gained compared with the next less effective and costly efficient strategy. From the efficient strategies, we selected the optimal strategy, again assuming a willingness to pay per QALY gained of $100 000.
Sensitivity Analyses
We repeated our analyses, assuming half and twice the base-case utility losses for colonoscopy, sigmoidoscopy, and complications; a utility loss of 0.12, 0.18, 0.24, and 0.70 QALYs for each LY with continuing care for stage I, II, III, and IV CRC, respectively; 25% higher and 25% lower costs for colonoscopy, sigmoidoscopy, and FIT; 25% higher and 25% lower costs for CRC care; twice the basecase miss rates for adenomas and CRC for both sigmoidoscopy and colonoscopy; no surveillance in patients with adenomas; 25% higher and 25% lower risk for CRC in all cohorts; and a willingness to pay per QALY gained of $50 000. Further, we explored the effect of FIT screening during 2 consecutive years.
This study did not include patient-specific information and was exempt from institutional review board review.
Role of the Funding Source
The study was supported by the National Cancer Institute. The funding source had no role in the study's design, conduct, and reporting.
RESULTS

Effectiveness
The effectiveness of CRC screening in unscreened elderly persons declined with increasing age ( Table 2 ). For example, 1-time colonoscopy screening prevented fewer CRC deaths (4.5 vs. 11.9 per 1000 persons) and resulted in fewer LYs gained (12.3 vs. 68.5 per 1000 persons) in healthy persons aged 90 years than in healthy persons aged 76 years. Moreover, whereas colonoscopy screening prevented 15.4 CRC cases per 1000 healthy persons aged 76 years, it resulted in overdiagnosis and hence overtreatment of 7.7 CRC cases per 1000 healthy persons aged 90 years. As a result, colonoscopy screening resulted in a positive overall effect on length and quality of life (that is, a net health benefit) in healthy persons aged 76 years (67.2 QALYs gained per 1000 persons) but in a net harm in healthy persons aged 90 years (1.7 QALYs lost per 1000 persons).
One-time sigmoidoscopy and, particularly, 1-time FIT screening were generally less effective than 1-time colonoscopy screening ( Table 2) . For example, in healthy persons aged 76 years, colonoscopy screening resulted in 67.2 QALYs gained per 1000 persons, whereas sigmoidoscopy and FIT screening resulted in 53.9 and 24.2 QALYs gained per 1000 persons, respectively. The only exceptions were seen at the most advanced ages, at which FIT screening was most effective-a result primarily explained by the 0 utility loss associated with this test. In persons with moderate and, particularly, severe comorbid conditions, screening was less effective than in persons without comorbid conditions (Appendix Table 3 , available at www.annals .org).
Costs
Whereas the effectiveness of screening in unscreened elderly persons declined with increasing age, the net costs of screening increased substantially ( Table 3) . While colonoscopy screening was associated with a lifetime cost of $725 000 per 1000 healthy persons aged 76 years, it was associated with a lifetime cost of $2 130 000 per 1000 healthy persons aged 90 years. This increase was again explained by the shift from preventing to overtreating CRC with age.
Besides being the most effective strategy, colonoscopy screening was also the most expensive ( Table 3) . For ex-ample, in healthy persons aged 76 years, the costs of colonoscopy screening were $725 000 per 1000 persons compared with $439 000 and $218 000 for sigmoidoscopy and FIT screening, respectively. In persons with moderate and, particularly, severe comorbid conditions, screening was not only less effective but also more costly (Appendix Table 4 , available at www.annals.org).
Cost-Effectiveness Compared With No Screening
As the effectiveness of screening declined with increasing age and the costs increased substantially, the costeffectiveness of screening deteriorated rapidly with age ( Figure 1) . In unscreened elderly persons without comorbid conditions, colonoscopy and sigmoidoscopy screening were cost-effective up to age 85 years, whereas FIT screening was cost-effective up to age 86 years. In elderly persons with moderate comorbid conditions, colonoscopy and sigmoidoscopy screening were cost-effective up to age 82 years, whereas FIT screening was cost-effective up to age 83 years. In persons with severe comorbid conditions, colonoscopy and sigmoidoscopy screening were costeffective up to age 79 years, whereas FIT screening was cost-effective up to age 80 years.
Incremental Cost-Effectiveness
We determined the optimal screening strategy for each cohort on the basis of the incremental cost-effectiveness ratios of the efficient screening strategies. In unscreened elderly persons with no comorbid conditions, colonoscopy screening was most effective and still cost-effective up to age 83 years (Appendix Table 5 [available at www.annals .org] and Figure 2 ), sigmoidoscopy screening was the optimal strategy at age 84 years, and FIT screening was the optimal strategy at ages 85 and 86 years. In elderly persons with moderate comorbid conditions, colonoscopy screening was the optimal strategy up to age 80 years, sigmoidoscopy screening was the optimal strategy at age 81 years, and FIT screening was the optimal strategy at ages 82 and 83 years. In persons with severe comorbid conditions, colonoscopy screening was the optimal strategy up to age 77 years, followed by sigmoidoscopy screening at age 78 years and FIT screening at ages 79 and 80 years.
Sensitivity Analyses
Besides comorbid condition level, the upper age at which screening was cost-effective was most sensitive to lowering the willingness-to-pay threshold to $50 000 per Table 1 . For example, when applying the 1-time colonoscopy screening strategy, 1000 persons have a screening colonoscopy in each cohort. Because the utility loss per screening colonoscopy is 0.0055 QALYs, the total utility loss due to screening colonoscopies is 5.5 QALYs in each cohort. The effect of screening on quantity and quality of life incorporated in 1 measure (i.e., the net health benefit of screening), calculated by adding LYs gained and all effects on quality of life. Discrepancies between the columns may occur due to rounding. ¶ Screening results in a gain of quality of life by preventing LYs with CRC care and a loss of quality of life by adding LYs with CRC care. The net effect can be a gain of quality of life (positive value) or a loss of quality of life (negative value). As a result of the shift from preventing to overdiagnosing CRC with increasing age, the net effect on quality of life becomes less favorable with age. Whereas 1-time colonoscopy screening in unscreened elderly without comorbid conditions reduced the total number of LYs with CRC care for stage III or IV CRC at age 76 y (Ϫ14 LYs per 1000 persons), it increased this number of LYs at age 90 y (ϩ16 LYs per 1000 persons). ** More detailed results for this cohort are given in Appendix Table 2 (available at www.annals.org).
Original Research Colorectal Cancer Screening in Unscreened Elderly Persons QALY gained (Appendix Table 6 , available at www.annals .org). Based on this threshold, screening unscreened elderly persons with no, moderate, and severe comorbid conditions should be considered up to age 84, 80, and 77 years, respectively. The upper ages at which screening should be considered were robust to all other sensitivity analyses.
The tests that were indicated at specific ages differed substantially between analyses (Appendix Table 6 ). Besides the threshold for the willingness to pay per QALY gained, the level of CRC risk and utility losses associated with colonoscopy, sigmoidoscopy, and complications were the most important factors in this respect.
In persons aged 84 years without comorbid conditions and persons aged 78 years with severe comorbid conditions, sigmoidoscopy screening was not cost-effective compared with FIT screening during 2 consecutive years (Appendix Table 6 ). In persons aged 85 years without comorbid conditions, persons aged 82 years with moderate comorbid conditions, and persons aged 79 and 80 years with severe comorbid conditions, FIT screening during 2 consecutive years was cost-effective compared with 1-time FIT screening.
DISCUSSION
Our study shows that in elderly persons without previous screening for CRC, screening remains cost-effective well beyond age 75 years, which is the recommended age to discontinue screening in adequately screened persons ( Table 4) . In unscreened elderly persons with no comorbid conditions, screening was cost-effective up to age 86 years. Screening with colonoscopy was most effective and still cost-effective up to 83 years, sigmoidoscopy was indicated at age 84 years, and FIT was indicated at ages 85 and 86 years. In unscreened elderly persons with moderate comorbid conditions, screening was cost-effective up to age 83 years (colonoscopy indicated up to age 80 years, sigmoidoscopy at age 81 years, and FIT at ages 82 and 83 years). In persons with severe comorbid conditions, screening was cost-effective up to age 80 years (colonoscopy indicated up to age 77 years, sigmoidoscopy at age 78 years, and FIT at ages 79 and 80 years).
In a situation when an elderly person is willing to have only 1 type of screening test, the cost-effectiveness of that test compared with no screening becomes relevant. In such a person without comorbid conditions, colonoscopy and sigmoidoscopy screening can be considered up to age 85 years and FIT screening can be considered up to age 86 years. The ages for similar persons with moderate comorbid conditions are 82 years for colonoscopy and sigmoidoscopy and 83 years for FIT; for persons with severe comorbid conditions, the ages are 79 years for colonoscopy and sigmoidoscopy and 80 years for FIT. CRC ϭ colorectal cancer; FIT ϭ fecal immunochemical test; LY ϭ life-year. * Results are based on a comparison with no screening, reported per 1000 persons, and discounted by 3% per year. Persons are classified as having no comorbid conditions if none of the following conditions are present: an ulcer, a history of acute myocardial infarction, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, cerebrovascular disease, chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS. † At very advanced age, the costs of screening colonoscopies and sigmoidoscopies show a slight decline. This is explained by the small observed decrease in the prevalence of adenomas/CRC at very advanced age (11-18, 20, 21) . ‡ Screening prevents costs by preventing LYs with CRC care and induces costs by adding LYs with CRC care. The net effect can be an increase in costs (positive value) or a decrease in costs (negative value).
§ Discrepancies between the columns may occur due to rounding.
More detailed results for this cohort are given in Appendix Table 2 (available at www.annals.org).
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Although the incidence of CRC increases up to very advanced ages (19) , the effectiveness of screening declines with increasing age. This decline is primarily explained by the increasing risk for other-cause death with age, which reduces both the probability that screening will prevent CRC death and the number of LYs gained if death is prevented. Moreover, the risks for screening-induced harms (colonoscopy-related complications and, more importantly, overdiagnosis and overtreatment of CRC) increase with age (9) . At the same time, the shift from preventing to overtreating CRC causes the net costs of screening to increase with age. Together, these phenomena explain the rapid deterioration of the cost-effectiveness of screening with increasing age.
Although colonoscopy every 10 years, sigmoidoscopy every 5 years, and FIT every year are almost equally effective when applied from age 50 to 75 years (1, 2), colonoscopy is more effective than sigmoidoscopy and FIT when only 1 screening examination is performed because of its greater overall sensitivity for adenomas and CRC. However, because colonoscopy is also more expensive than sigmoidoscopy and FIT and because the effectiveness of all screening tests is marginal at very advanced ages, screening with colonoscopy is not cost-effective compared with sigmoidoscopy and FIT at the most advanced ages at which screening should be considered.
Screening remains cost-effective up to a more advanced age in persons without comorbid conditions than in those with comorbid conditions because their more favorable life expectancy increases the probability that screening will prevent CRC, thus increasing the effectiveness of screening while simultaneously reducing the costs of CRC care.
To our knowledge, our study is the first to investigate the net health benefit and the cost-effectiveness of CRC screening in persons older than 75 years without previous screening. An earlier study by Ko and Sonnenberg (7) demonstrated that the effectiveness of screening for preventing CRC death declines with increasing age, whereas the probability of screening-related complications increases Results are presented per 1000 persons and discounted by 3% per year. Persons are classified as having moderate comorbid conditions if they have an ulcer, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, cerebrovascular disease, or a history of acute myocardial infarction; severe comorbid conditions if they have chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and no comorbid conditions if none of these conditions are present. The dashed line indicates a willingness to pay per QALY gained of $100 000. Screening strategies costing less than $100 000 per QALY gained are considered cost-effective. Asterisks for missing screening strategies indicate that they were associated with a net health loss rather than a benefit (Appendix Table 3 [available at www.annals.org] and Table 2 ). FIT ϭ fecal immunochemical test; QALY ϭ quality-adjusted life-year.
Original Research Colorectal Cancer Screening in Unscreened Elderly Persons with age. Further, a study by Lin and colleagues (8) demonstrated that the number of LYs gained by screening declines with age, resulting in an increase in the number of colonoscopies required per LY gained. However, neither study considered costs or measured the overdiagnosis and overtreatment of cancer, which is the most important adverse effect of screening in elderly persons. As a result, these studies cannot easily be used to determine whether unscreened elderly persons should be screened. Some other, more recent studies have suggested that screening should be continued after age 75 years (3, 4) . However, these studies did not distinguish between adequately Results are presented per 1000 persons and discounted by 3% per year. Persons are classified as having moderate comorbid conditions if they have an ulcer, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, cerebrovascular disease, or a history of acute myocardial infarction; severe comorbid conditions if they have chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis, or AIDS; and no comorbid conditions if none of these conditions are present. In elderly persons without previous screening with no, moderate, or severe comorbid conditions, none of the screening strategies are cost-effective from age 87, 84, and 81 years onward, respectively (Figure 1) . For each age, the efficient screening strategies are connected by an efficiency frontier. A solid line indicates that the ICER of a screening strategy is Ͻ$100 000 per QALY gained, implying that the strategy is considered cost-effective. A dashed line indicates that the ICER of a screening strategy exceeds $100 000 per QALY gained, implying that the strategy is not considered cost-effective. FIT ϭ fecal immunochemical test; ICER ϭ incremental cost-effectiveness ratio; QALY ϭ quality-adjusted life-year. 
Colorectal Cancer Screening in Unscreened Elderly Persons www.annals.orgscreened elderly persons and elderly persons without previous screening. Further, these studies based their conclusions only on CRC incidence data. The USPSTF selected its recommended screening strategies on the basis of the number of colonoscopies required per LY gained (undiscounted) (1, 2), but we based our conclusions on the costs per QALY gained (discounted at 3% per year). We did so for 2 reasons. First, policymakers should be able to compare the efficiency of a wide range of health interventions; the USPSTF outcome measure does not allow for this. Second, we believe that effects on both length and quality of life should be considered. However, the 2 approaches led to screening recommendations associated with similar numbers of colonoscopies per LY gained: Screening with colonoscopy as recommended by the USPSTF (that is, at ages 50, 60, and 70 years) required 30 to 35 colonoscopies per LY gained (2) . Also, screening with colonoscopy in unscreened persons aged 83 years with no comorbid conditions, for example, required 32 colonoscopies per LY gained.
Our study has 2 main limitations. First, we did not perform separate analyses by sex and race. However, we do not expect that results from such analyses would have differed much from those reported here because a substantial part of the difference in life expectancy between men and women and between black and white persons is explained by differences in the prevalence of moderate and severe comorbid conditions. Also, persons with the most favorable life expectancy (that is, white females) are at lowest risk for CRC and vice versa. Hence, the effect of life expectancy on the cost-effectiveness of screening is counterbalanced by the effect of CRC risk (at least partially) (35) . Second, we did not perform separate analyses for identifiable high-risk subgroups, such as elderly persons with a family history of CRC (36) . In some of these subgroups, screening may be cost-effective up to a more advanced age.
Our analysis highlights some future research directions. First, future research should determine the optimal number of FIT screenings in elderly persons who are relatively young and not willing to have a screening colonoscopy or sigmoidoscopy. Second, other research should study how the benefits, burden, and harms of screening affect patient decisions about CRC screening. Third, studies evaluating the appropriate age to stop screening by comorbid condition level are also required for adequately screened persons.
In conclusion, our study demonstrates that in the 23% of U.S. elderly persons without previous screening, CRC screening should be considered well beyond age 75 years. In unscreened elderly persons with no comorbid conditions, CRC screening should be considered up to age 86 years (up to age 83 years for those with moderate comorbid conditions and up to age 80 years for those with severe comorbid conditions). Screening with colonoscopy is indicated at most ages. 
APPENDIX: MISCAN-COLON General Model Structure
MISCAN-Colon is a stochastic microsimulation model for CRC programmed in Delphi (Borland Software, Scotts Valley, California). It can be used to explain and predict trends in CRC incidence and mortality rates and to quantify the effects and costs of primary prevention of CRC, screening for CRC, and surveillance after polypectomy.
The term "microsimulation" implies that persons are moved through the model one at a time, rather than as proportions of a cohort. This allows future state transitions to depend on past transitions, giving the model a "memory." Further, unlike most traditional Markov models, MISCAN-Colon does not use yearly transition probabilities; instead, it generates durations in states, thereby increasing model flexibility and computational performance. The term "stochastic" implies that the model simulates sequences of events by drawing from distributions of probabilities or durations, rather than using fixed values. Hence, the results of the model are subject to random variation.
MISCAN-Colon consists of 3 modules: a demography module, natural history module, and screening module.
The Demography Module
Using birth and life tables that are representative of the population under consideration, MISCAN-Colon draws a date of birth and date of non-CRC death for each person simulated. In MISCAN-Colon, the maximum age a person can achieve is exactly 100 years.
The Natural History Module Transitions
As each simulated person ages, 1 or more adenomas may develop (Appendix Figure 1) . These adenomas can be either progressive or nonprogressive. Both progressive and nonprogressive adenomas can grow in size from small (Յ5 mm) to medium (6 to 9 mm) to large (Ն10 mm); however, only progressive adenomas can develop into preclinical cancer. Preclinical cancer may progress through stages I to IV; however, during each stage, CRC may be diagnosed because of symptoms. After clinical diagnosis, CRC survival is simulated using age-, stage-, and localization-specific survival estimates for clinically diagnosed CRC obtained from a study by Rutter and colleagues (10) . For persons with synchronous CRCs at diagnosis, the survival of the most advanced cancer is used. The date of death for patients with CRC is set to the earliest simulated death (either due to CRC or another cause).
Transition Probabilities and Durations in States
A person's risk for adenomas depends on the person's age and risk index. As a result of the latter, most persons develop no adenomas and some develop many. We assumed that the distribution of adenomas over the colon and rectum equals the distribution of cancer cases as seen in SEER before the introduction of screening (19) . The age-specific onset of adenomas and the dispersion of the personal risk index were calibrated to data on the prevalence and multiplicity distribution of adenomas as seen in autopsy studies (Appendix Figure 2) (11-18, 20, 21) . The agespecific probability of adenoma progressivity and the age-and localization-specific transition probabilities between preclinical cancer stages and between preclinical and clinical cancer stages were simultaneously calibrated to SEER data on the age-, stage-, and localization-specific incidence of CRC as seen before the introduction of screening (Appendix Figure 3) (19) .
The average durations of the preclinical cancer stages were calibrated to the rates of screen-detected and interval cancer seen in randomized, controlled trials (RCTs) evaluating screening using guaiac fecal occult blood tests (23, 24, 26) . This exercise has been described extensively by Lansdorp-Vogelaar and colleagues (25) . The average duration from the emergence of an adenoma (state 2) until progression into preclinical cancer (state 7) (that is, the adenoma dwell time) was calibrated to the rates of interval cancer (including surveillance-detected cancer) seen in a RCT evaluating 1-time sigmoidoscopy screening (Appendix Figure 4 ) (22) . We assumed an equal overall dwell time for adenomas developing into CRC from a medium size (30% of all CRCs) and from a large size (70% of all CRCs). All durations in the adenoma and preclinical cancer phases were drawn from exponential distributions. Durations within the adenoma and preclinical cancer phases were assumed to be perfectly correlated (that is, if a small adenoma grows into a medium-sized adenoma rapidly, it will also grow into a large adenoma or develop into CRC rap-
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www.annals.orgidly); however, durations in the adenoma phase were assumed to be uncorrelated with durations in the preclinical cancer phase (that is, a rapidly growing adenoma does not necessarily develop into a rapidly progressing cancer). The proportion of mediumsized, nonprogressive adenomas growing large and the average duration in the medium-size, nonprogressive adenoma state (state 5) were calibrated to size-specific adenoma detection rates seen in a Dutch RCT on colonoscopy screening (data not shown).
The Screening Module
Screening will alter some of the simulated life histories: Some cancer cases will be prevented by the detection and removal of adenomas; other cancer cases will be detected in an earlier stage with a more favorable survival. Because the stage-specific survival of screen-detected CRC as seen in RCTs on guaiac fecal occult blood testing was substantially more favorable than that of clinically detected CRC, even after correcting for lead-time bias (25) , we assigned those screen-detected cancer cases that would have been clinically detected in the same stage a survival corresponding to a cancer that is 1 stage less progressive. Hence, a cancer screen-detected in stage II that would also have been clinically diagnosed in stage II is assigned the survival of a clinically diagnosed stage I cancer. The only exceptions were screendetected stage IV cancer cases. These cases were always assigned the survival of a clinically diagnosed stage IV cancer.
Besides modeling positive health effects of screening, we also modeled colonoscopy-related complications and overdiagnosis and overtreatment of CRC (that is, the detection and treatment of cancer that would not have been diagnosed without screening) (9) .
Integrating Modules
The demography module generates a date of birth and date of non-CRC death for each person simulated, creating a life history without adenomas or CRC. In patient A in Appendix Figure 5 , the natural history module generates an adenoma. This adenoma progresses into preclinical cancer, which is diagnosed because of symptoms in stage II and results in CRC death before non-CRC death would have occurred. In the screening module, a screening examination is simulated, indicated by the blue arrow. During this examination, the adenoma is detected and, as a result, both CRC and CRC death are prevented. Hence, in patient A, screening prolongs life by the amount indicated by the green arrow. Patient B also develops an adenoma, and although this adenoma does progress into preclinical cancer, patient B would never have been diagnosed with CRC in a scenario without screening (see Life History 2). However, during the screening examination simulated in the screening module, again indicated by the blue arrow, CRC is screen-detected in stage I. Hence, in this patient, screening results in overdiagnosis of CRC: It detects a cancer that would never have been diagnosed in a scenario without screening. Hence, screening does not prolong life, but it does result in additional LYs with CRC care (overtreatment) as indicated by the red arrow. CRC ϭ colorectal cancer; FIT ϭ fecal immunochemical test. * We assumed that in 10% of all negative colonoscopy results and in 8% of all negative sigmoidoscopy results a nonadenomatous lesion was detected, resulting in a polypectomy or a biopsy, respectively. † The sensitivity of colonoscopy and sigmoidoscopy for the detection of adenomas and CRC within the reach of the endoscope was obtained from a systematic review on miss rates seen in tandem colonoscopy studies (39). ‡ The test characteristics of FIT were fitted to the positivity rates and detection rates seen in the first screening round of the Dutch screening trial. We assumed that the probability that a CRC bleeds and thus the sensitivity of FIT for CRC depends on the time until clinical diagnosis, in concordance with our findings for guaiac fecal occult blood tests (25) . § The reach of sigmoidoscopy was obtained from a study by Painter et al (38). Age-specific risks for complications of colonoscopy requiring a hospital admission or emergency department visit were obtained from a study by Warren et al (9) . ¶ The mortality rate associated with colonoscopies with a polypectomy was derived by multiplying the risk for a perforation obtained from a study by Warren et al (9) by the risk for death given a perforation obtained from a study by Gatto et al (37). † Discrepancies between columns may occur due to rounding. ‡ Because screening results in prevention and earlier detection of CRC, it reduces the total numbers of LYs with initial care for CRC, terminal care for CRC, and terminal care for other causes in patients with CRC; however, because screening improves the average survival of patients with CRC, it increases the total number of LYs with continuing care for CRC. § The increase in LYs with continuing care for stage III CRC is explained by the more favorable average survival that we model for screen-detected vs. clinically detected cancer as described in the Appendix. The number of LYs gained by screening ( Table 2) . ¶ The number of QALYs gained by screening ( Table 2) . ** The costs of screening ( Table 3) . Table 1 . For example, when applying the 1-time colonoscopy screening strategy, 1000 persons have a screening colonoscopy in each cohort. Because the utility loss per screening colonoscopy is 0.0055 QALYs, the total utility loss due to screening colonoscopies is 5.5 QALYs in each cohort. The effect of screening on quantity and quality of life incorporated in 1 measure (i.e., the net health benefit of screening), calculated by adding LYs gained and all effects on quality of life. Discrepancies between the columns may occur due to rounding. ¶ Screening results in a gain of quality of life by preventing LYs with CRC care and a loss of quality of life by adding LYs with CRC care. The net effect can be a gain of quality of life (positive value) or a loss of quality of life (negative value). As a result of the shift from preventing to overdiagnosing CRC with increasing age, the net effect on quality of life becomes less favorable with age. * Persons are classified as having moderate comorbid conditions if they have an ulcer, rheumatologic disease, peripheral vascular disease, diabetes, paralysis, cerebrovascular disease, or a history of acute myocardial infarction; severe comorbid conditions if they have chronic obstructive pulmonary disease, congestive heart failure, moderate or severe liver disease, chronic renal failure, dementia, cirrhosis and chronic hepatitis or AIDS; and no comorbid conditions if none of these conditions are present. 
Appendix
Seen in SEER 1975-1979 Simulated
Bars above and below the diamonds indicate 95% CIs. CRC ϭ colorectal cancer; SEER ϭ Surveillance, Epidemiology, and End Results. Bars above and below the diamonds indicate 95% CIs. CRC ϭ colorectal cancer; UK ϭ United Kingdom.
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